202 related articles for article (PubMed ID: 22743729)
1. Tacrolimus-induced nephrotoxicity and genetic variability: a review.
Gijsen VM; Madadi P; Dube MP; Hesselink DA; Koren G; de Wildt SN
Ann Transplant; 2012; 17(2):111-21. PubMed ID: 22743729
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients.
Sallustio BC; Noll BD; Hu R; Barratt DT; Tuke J; Coller JK; Russ GR; Somogyi AA
Br J Clin Pharmacol; 2021 Oct; 87(10):3901-3909. PubMed ID: 33646566
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
6. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
Hesselink DA; Bouamar R; Elens L; van Schaik RH; van Gelder T
Clin Pharmacokinet; 2014 Feb; 53(2):123-39. PubMed ID: 24249597
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
[TBL] [Abstract][Full Text] [Related]
8. The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells.
Knops N; van den Heuvel LP; Masereeuw R; Bongaers I; de Loor H; Levtchenko E; Kuypers D
Mol Pharm; 2015 Mar; 12(3):758-68. PubMed ID: 25590378
[TBL] [Abstract][Full Text] [Related]
9. Severe acute nephrotoxicity in a kidney transplant patient despite low tacrolimus levels: a possible interaction between donor and recipient genetic polymorphisms.
Quaglia M; Terrazzino S; Boldorini R; Stratta P; Genazzani AA
J Clin Pharm Ther; 2013 Aug; 38(4):333-6. PubMed ID: 23574377
[TBL] [Abstract][Full Text] [Related]
10. Association of CYP3A5, CYP2C8, and ABCB1 Polymorphisms With Early Renal Injury in Chinese Liver Transplant Recipients Receiving Tacrolimus.
Deng R; Liao Y; Li Y; Tang J
Transplant Proc; 2018 Dec; 50(10):3258-3265. PubMed ID: 30577195
[TBL] [Abstract][Full Text] [Related]
11. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
12. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
14. The Cytochrome P450 3A5 Non-Expressor Kidney Allograft as a Risk Factor for Calcineurin Inhibitor Nephrotoxicity.
Udomkarnjananun S; Townamchai N; Chariyavilaskul P; Iampenkhae K; Pongpirul K; Sirichindakul B; Panumatrassamee K; Vanichanan J; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K
Am J Nephrol; 2018; 47(3):182-190. PubMed ID: 29539600
[TBL] [Abstract][Full Text] [Related]
15. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.
Yanik MV; Seifert ME; Locke JE; Hauptfeld-Dolejsek V; Crowley MR; Cutter GR; Mannon RB; Feig DI; Limdi NA
Pediatr Transplant; 2019 Aug; 23(5):e13494. PubMed ID: 31124575
[TBL] [Abstract][Full Text] [Related]
16. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
[TBL] [Abstract][Full Text] [Related]
17. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
[TBL] [Abstract][Full Text] [Related]
18. Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus.
Yan L; Li Y; Tang JT; An YF; Wang LL; Shi YY
Pharmacogenomics; 2016 Feb; 17(3):249-57. PubMed ID: 26784512
[TBL] [Abstract][Full Text] [Related]
19. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.
Metalidis C; Lerut E; Naesens M; Kuypers DR
Transplantation; 2011 May; 91(10):1098-102. PubMed ID: 21544031
[TBL] [Abstract][Full Text] [Related]
20. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
